Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP3 | O14638 | 13/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 11/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 10/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6017758 | 0.80 | ABL1 (0.39) | ENPP3ENPP1ENPP2HTR6MAPT | |
| SCHEMBL27657636 | 0.78 | AKR1C3 (0.41) | ENPP3ENPP1ENPP2HTTLMNA | |
| SCHEMBL5037857 | 0.76 | ENPP3 (0.40) | ENPP3ENPP1ENPP2HTR6 | |
| SCHEMBL6018023 | 0.76 | IDO1 (0.43) | ENPP3ENPP1ENPP2HTR6MAPT | |
| SCHEMBL5042961 | 0.75 | HTR6 (0.45) | HTR6HTTLMNA | |
| SCHEMBL5036480 | 0.75 | NPC1 (0.53) | ENPP3ENPP1ENPP2MAPTHTT | |
| SCHEMBL5042870 | 0.75 | ENPP3 (0.48) | ENPP3ENPP1ENPP2 | |
| SCHEMBL5033423 | 0.75 | ENPP3 (0.40) | ENPP3ENPP1ENPP2HTR6MAPT | |
| SCHEMBL5041053 | 0.74 | NPC1 (0.52) | ENPP3ENPP1ENPP2MAPTHTT | |
| SCHEMBL5035960 | 0.74 | ENPP3 (0.39) | ENPP3ENPP1ENPP2MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432417-B1 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | AVENTIS PHARMA SA (FR) | 2008-02-20 | — | — | EP | disclosed |
| EP-1432417-A2 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | Aventis Pharma S.A. (FR) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003028721-A2 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | AVENTIS PHARMA S.A. (FR) | 2003-04-10 | — | — | WO | disclosed |
| EP-1298125-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | Aventis Pharma S.A. (FR) | 2003-04-02 | — | — | EP | disclosed |